Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases

Urology

Volumn 53, Issue 5, 1999, Pages 939-944

  Darson, Micheal F ^a   Pacelli, Anna ^b   Roche, Patrick ^b   Rittenhouse, Harry G ^c   Wolfert, Robert L ^c   Saeid, Mohammad S ^c   Young, Charles Y F ^a   Klee, George G ^b   Tindall, Donald J ^a   Bostwick, David G ^a,b  

^a DEPARTMENT OF UROLOGY   (United States)

^b MAYO CLINIC   (United States)

^c Hybritech Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER RECURRENCE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION;

EID: 0033046353     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00637-2     Document Type: Article

References (24)

1. McCormack R.T., Rittenhouse H.G., Finlay J.A., et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 45:1995;729-744.
2. Ruckle H.C., Klee G.G., Oesterling J.E. Prostate-specific antigen: critical issues for the practicing physician. Mayo Clin Proc. 69:1994;59-68.
3. Brawer M.K., Meyer G.E., Letran J.L., et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 52:1998;372-378.
4. Darson M.F., Pacelli A., Roche P., et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology. 49:1997;857-862.
5. Wang T.J., Hill T.M., Sokoloff R.L., et al. Dual monoclonal antibody immunoassay for free prostate-specific antigen. Prostate. 28:1996;10-16.
6. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
7. Rittenhouse HG, Tindall D, Klee GG, et al: Characterization and evaluation of hK2: a potential prostate cancer marker, closely related to PSA, in Murphy GP, and Khoury S (Eds): Proceedings of the First International Consultation on Prostate Cancer, June 1996, Monaco. Jersey, Channel Islands, Scientific Communication International, 1997.
8. Charlesworth M.C., Young C.Y.-F., Klee G.G., et al. Detection of a prostate-specific protein, human glandular kallikrein 2 (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology. 49:1997;487-493.
9. Lilja H. Structure, function and regulation of the enzyme activity of prostate-specific antigen. World J Urol. 11:1993;188-191.
10. Young C.Y.-F., Andrews P.E., Montgomery B.T., et al. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry. 31:1992;818-824.
11. Chapdelaine P., Paradis G., Tremblay R.R., et al. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett. 236:1988;205-208.
12. Murtha P., Tindall D.J., Young C.Y.-F. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry. 32:1993;6459-6464.
13. Grauer L.S., Charlesworth C., Saedi M.S., et al. Identification of human glandular kallikrein hK2 from LNCaP cells. J Androl. 17:1996;355-359.
14. Finlay J.A., Evans C.L., Day J.R., et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate specific antigen cross-reactivity. Urology. 51:1998;804-809.
15. Young C.Y.-F., Seay T., Hogen K., et al. Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer. Prostate Suppl. 7:1996;17-24.
16. Bostwick D.G. High grade prostatic intraepithelial neoplasia: the most likely precursor of prostate cancer. Cancer. 75:1995;1823-1836.
17. Bostwick D.G., Pacelli A., Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate. 29:1996;117-134.
18. Contractor H., Ruschoff J., Ulshofer B., et al. Silver-stained structures in prostatic carcinoma: evaluation of diagnostic and prognostic relevance by automated image analysis. Urol Int. 46:1991;9-14.
19. Sakai H., Yogi Y., Minami Y., et al. Prostate-specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma. J Urol. 149:1993;1020-1023.
20. Sakai H., Shiraishi K., Minami Y., et al. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma. Prostate. 19:1991;265-272.
21. Cohen R., Haffejee Z., Stelle G.S., et al. Advanced prostate cancer with normal serum prostate-specific antigen values. Arch Pathol Lab Med. 118:1994;1123-1126.
22. Gray E., Allison L.J., Edgar S., et al. Prostatic adenocarcinoma labeled with a monoclonal antibody and polyclonal serum: a quantitative assessment. Br J Urol. 78:1996;104-108.
23. Wang T.J., Finlay J.A., Mikolajczyk S., et al. Analysis of cross-reactivity of anti-PSA monoclonal antibodies with recombinant human glandular kallikrein (abstract). J Urol. 155:(suppl):1996;695A.
24. Diamandis E.P. Prostate cancer, prostate-specific antigen, and the polymerase chain reaction. Clin Chem. 41:1995;177-179.